期刊文献+

血清淀粉样蛋白A、干扰素-G诱导蛋白10及降钙素原在AECOPD中的诊断意义 被引量:18

Roles of SAA,IP-10 and PCT in differential diagnosis of AECOPD
下载PDF
导出
摘要 目的:评价血清血清淀粉样蛋白A(SAA)、血清干扰素G诱导蛋白10(IP-10)及降钙素原(PCT)在慢性阻塞性肺疾病急性加重期(AECOPD)患者中的诊断价值。方法:(1)选取AECOPD患者60例,s COPD患者52例,对照组28例,构成随机平行资料。(2)另随机选择其中19例AECOPD患者及其稳定期构成COPD急性加重-稳定期配对资料。采用酶联免疫法测定各组患者血清标记物水平,比较并分析其异同。结果:(1)AECOPD组SAA浓度与s COPD组SAA浓度差异有统计学意义(P<0.05)。(2)AECOPD组与s COPD组血清IP-10浓度比较有统计学差异(P<0.05)。(3)AECOPD组与s COPD组血清PCT浓度比较无统计学差异(P>0.05)。结论:AECOPD组血清SAA和IP-10浓度较s COPD组升高,有助于AECOPD的诊断,其诊断敏感度及特异度分别为100.0%、54.9%,96.1%、75.0%。本研究结果中PCT不能用于鉴别AECOPD与s COPD。 Objective To assess the clinical significance of SAA,IP-10 and PCT in the diagnosis of AECOPD.Methods Sixty AECOPD patients,52 with s COPD,and 28 healthy subjects were assigned to three groups.Clinical data and serum specimen were obtained from another 19 AECOPD patients at stable stage as AECOPDs COPD group.Serum levels of SAA,IP10 and PCT were quantitatively measured by ELISA.Levels of multiple serum markers were statistically compared among different groups.Results The concentration of SAA significantly differed between the AECOPD and s COPD groups(P〈0.05),so did the concentration of IP-10(P〈0.05);no statistical significance was found in terms of serum PCT concentration between the two groups(P〈0.05).Conclusions As compared with the s COPD group,levels of serum SAA and IP-10 in the AECOPD group were significantly elevated,which is helpful in the diagnosis of AECOPD with a sensitivity and specificity of 100% and54.9% for SAA,and 96.1% and 75.0% for IP-10.However,PCT level failed to identify AECOPD from s COPD.
出处 《实用医学杂志》 CAS 北大核心 2016年第8期1277-1279,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献10

  • 1GUADE GS,RAJESH BP,CHAUDHURY A,et al.Outcomes associated with acute exacerbations of chronic obstructive pul- monary disorder requiring hospitalization[J].Lung India,2015,32(5):465-472.
  • 2LACOMA A,PRAT C,ANDREO F,DOMINGUEZ J.Biomark- ers in the management of COPD[J].Eur Respir Rev,2009,18(112):96-104.
  • 3SAPEY E,STOCKLEY RA.COPD exacerbations.2:aetiology [J].Thorax,2006,61(3):250-258.
  • 4JeNNIFER K.QUINT.Serum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD[J].Chest,2010,137(4):812-822.
  • 5JUNYAN QU.Evaluation of procalcitonin,C-reactive protein,interleukin-6& serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients[J].Indian J Med Res,2015,141(3):315-321.
  • 6何艳菊,赵海金,蔡绍曦.动态监测降钙素原对判断细菌性医院获得性肺炎患者预后的意义[J].实用医学杂志,2014,30(6):918-921. 被引量:16
  • 7FINNEY LJ,RITCHIE A,POLLARD E,et al.Lower airway colonization and inflammatory response in COPD:a focus on Haemophilus influenzae[J].nt J Chron Obstruct Pulmon Dis,2014,9:1119-1132.
  • 8SAPEY E,STOCKLEY RA.COPD exacerbations.2:aetiology [J].Thorax,2006,61(3):250-258.
  • 9BAI CX.Expert consensus on acute exacerbation of chronic ob- structive pulmonary disease in the People's[J].Republic of China,2014,9(1):381-395.
  • 10DANIELS JM,SCH00RL M,SNUDERS D,et al.Procalcitonin vs Creactive protein as predictive markers of response to antibiot- ic therapy in acute exacerbations of COPD[J].Chest,2010,138(5):1108-1115.

二级参考文献18

  • 1周锦桃,刘朝晖.医院获得性肺炎的病原学及诊断标准研究进展[J].国际呼吸杂志,2007,27(12):936-939. 被引量:21
  • 2Murthy R. Implementation of strategies to control antimicrobial resistance [J]. Chest, 2001,119(2) :405-411.
  • 3The American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated Pneumonia [J]. Am J Respir Crit Care Med, 2005,171(4) :388-416.
  • 4Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome[J]. Clin Infect Dis, 2010,51 ( 1 ) : 131-135.
  • 5Lee JY, Hwang SJ, Shim JW, et al. Clinnical significance of serum procalcitonin in parients with community-acquired lobar pneumonia [J]. Korean J Lab Med, 2010,30(4):406-413.
  • 6Polzin A, Pletz M, Lee N, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis [J]. Eur Respir J, 2003,21(6) :939-943.
  • 7Schuetz P, Batschwaroff M, Dusemund F, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post- study survey [J]. Eur J Clin Microbiol Infect Dis, 2010,29(3): 269-277.
  • 8Lee M, Snyder A. The Role of Procalcitonin in Commmunity- Acquied Pneumonia: a literature review [J]. Adv Emerg Nurs J, 2012,34(3) :259-271.
  • 9Schuetz P, Christ-Crain M, Mueller B. Procalcitonin and other biomakers to improve assessment and antibiotic stewardship in infections-hope for hype [J]. Swiss Med Wkly, 2009,139(23- 24) : 318-326.
  • 10Horie M, Ugajin M, et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia [J]. Am J Med Sci, 2012,343 ( 1 ) : 30-35.

共引文献15

同被引文献168

引证文献18

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部